ADDISON IN X-LINK ADRENOLEUKODYSTROPHY (X- ALD): Phenotype and genotype of 12 cases Nguyen Ngoc Khanh 1, Vu Chi Dung 1 , Shimozawa N 2. , Bui Phuong Thao.

Slides:



Advertisements
Similar presentations
MOTOR NEURON DISEASE The motor neuron diseases (or motor neuron diseases) (MND) are a group of neurological disorders that selectively affect motor neurons.
Advertisements

Unusual Brain Lesion with a Usual Cause
METABOLISM OF 8-ISO-PGF2α IS IMPAIRED BY CLA IN FIBROBLASTS FROM PATIENTS AFFECTED BY X-ALD A. Petroni 1, M. Blasevich 1, R. Carissimi 1, S. Mattavelli.
Demyelinating Diseases. Demyelination is a common degenerative change in the nervous system secondary to neuronal or axonal injury, But in the group of.
First Department of Internal Medicine, General Hospital of Rhodes,
AN INTERESTING CAUSE FOR ATAXIA ID NO: year old male patient, 1 st child of non consanguinous marriage c/o progressive unsteadiness while walking.
Approach to Nervous System Dr. Amal Alkhotani MD, FRCPC Neurology,EEG & Epilepsy
Clinical assessment Aims (1) Is it a stroke? (2) What part of the brain is affected? (3) What caused this stroke? Is it a haemorrhage or an infarct? Can.
Introduction to the ALD Newborn Screening Study to be performed at Frederick Memorial Hospital and three other Maryland Hospitals PART 1: BACKGROUND INFORMATION.
Imaging and clinical features of metachromatic leukodystrophy: a study in 9 Tunisian children C. Drissi, I. Kraoua*, I. Rebaï*, S. Nagi, N. Gouider-Khouja*,
Pelizaeus-Merzbacher Disease
Newborn Screening for X-linked Adrenoleukodystrophy (X-ALD): Update from the Condition Review Workgroup Alex R. Kemper, MD, MPH, MS May 12, 2015.
 What’s a “mutagen”?  What does a mutation do to DNA?  If a mutation affects a gene, then what might happen to the protein sequence?
An Update in Genetics of Epilepsy
Brain Tumors Maria Rountree. Most common types of brain tumors The most common childhood tumors are: The most common childhood tumors are: 1. Astrocytoma.
1 Genetic Disorders Gaia Scerif Room 426, Ext Office Hours: Thurs 1-3.
Adrenoleukodystrophy By Nicolette Laird Lorenzo’s Oil.
______ _______ ______ _______ Genetic Diseases. Basic Punnett Square In this scenario, both parents are heterozygous for a particular allele A = dominant.
Multiple Sclerosis Rohith M. Reddy. Multiple sclerosis (MS) involves an immune-mediated process in which an abnormal response of the body’s immune system.
X-Linked Adrenoleukodystrophy (ALD)
Day one Adrenoleukodystrophy Called ALD a rare, inherited metabolic disorder the fatty covering (myelin sheath) on nerve fibers in the brain is lost,
Initial presentation of multiple sclerosis in northern Iran; Is there any comparison to other countries Initial presentation of multiple sclerosis in northern.
MPZ mutations associated with deafness and abnormal pupillar reaction in Czech CMT2 patients, but also in HMSN III patients. P. Seeman 1, K. Huehne 2,
10 Second Case Studies Round 2: Degenerative Neurological Conditions.
Hemophilia Research Center for Genetic Engineering and Biotechnology “Georgi D. Efremov”, MASA What is: Hemophilia is an X-linked congenital bleeding disorder.
ABC half-transporter relative gene expression and metabolism of conjugated linoleic acid (CLA) in X- linked Adrenoleukodystrophy Petroni A 1. 1, Carissimi.
Int J MS Care 7: , 2005/2006. Jan 9 & 10, Clinical Stabilization of a MS Patient after Tonsillectomy presented by Michael C. Levin, MD Department.
This lecture was conducted during the Nephrology Unit Grand Ground by a Sub-intern under Nephrology Division, Department of Medicine in King Saud University.
Adrenoleukodystrophy (X-ALD)
A Diagnostic Testing Service for Hypophosphatemic Rickets
Lecture 6. Functional Genomics: DNA microarrays and re-sequencing individual genomes by hybridization.
Molecular Genetics in the Von Willebrand disease Ghasem Rastegarlari.
This is a work in progress! Subject to change in content and points offered for each section! Further discussion in class will clarify details! PROJECT.
The Child with Motor Weakness
Children’s Hospital of Philadelphia Glycomics Profile Analysis by MALDI TOF/MS in Human CSF Xueli Li, Ph.D., Children’s Hospital of Philadelphia.
Leukodystrophies Costello, D. J., A. F. Eichler, and F. S. Eichler. "Leukodystrophies: Classification, Diagnosis, and Treatment." Neurologist 15, no. 6.
2 pt 3 pt 4 pt 5 pt 1 pt 2 pt 3 pt 4 pt 5 pt 1 pt 2 pt 3 pt 4 pt 5 pt 1 pt 2 pt 3 pt 4 pt 5 pt 1 pt 2 pt 3 pt 4 pt 5 pt 1 pt All about the Neuron The.
Dentatorubral- pallodoluysian Atrophy (DRPLA). DRPLA Trinucleotide Repeat Disorder Trinucleotide Repeat Disorder CAG repeat on Chromosome 12 CAG repeat.
Neurobiology of Dementia Majid Barekatain, M.D., Associate Professor of Psychiatry Neuropsychiatrist Isfahan University of Medical Sciences Ordibehesht.
Neurogenetic Self-Assessment John K. Fink, M.D., Professor, Department of Neurology, University of Michigan Feb. 24, 2009 Movement disorders: Parkinson’s,
DAY 2 Unit 3 Inheritance and Molecular Genetics 1.
6-year-old boy with progressive neurologic decline Teaching NeuroImages Neurology Resident and Fellow Section © 2015 American Academy of Neurology.
Printing: Your printer might not print the same way our printers do, so make sure to try a couple of test prints. If things aren’t aligning quite right,
Wernicke’s encephalopaty: the best way to make early diagnosis D.MACHADO* – A.BOCCHIO *– A.M.ROSANO’*- M.OGGERO*- N.MILLOZ° – G.DOVERI°– T.MELONI* *Radiology.
Canavan Disease.
The Child with Motor Weakness Neurology Module Pediatrics II.
Electrophysiology & Leukodystrophies Shahriar Nafissi Department of Neurology Tehran University of Medical Sciences.
Pt ZJ 19yo M that presented to Seattle Children’s for evaluation of 3 lesions found on recent PET CT ◦ One large mass in the posterior mediastinum just.
Hypotonia, neuropathies and myopathies
Hemophilia in Canis familiaris (dogs). General information MIM number: MIM number: MIA number: MIA number:
1 Finding disease genes: A challenge for Medicine, Mathematics and Computer Science Andrew Collins, Professor of Genetic Epidemiology and Bioinformatics.
Patterns of single gene inheritance Mahmoud A. Alfaqih BDS PhD Jordan University of Science and Technology School of Medicine Department of Biochemistry.
CDKL5 gene related epileptic encephalopathy in Estonia: a case presentation Klari Noormets 1,2, Katrin Õunap 2,3, Ulvi Vaher 1, Tiina Talvik 1,2, Inga.
Picture of Speaker Here Steven A. Skinner, M.D. Director Greenwood Genetic Center Genetics 101: What do MECP2, CDKL5 and FOXG1 have to do with one another?
CEREBROTENDINOUS XANTHOMATOSIS Sheri Harder* Paggie Kim * Miriam Peckham * Teresa LaBarte ŧ Departments of Radiology (Division of Neuroradiology)* and.
J Am Coll Cardiol 2007;50:2399–403 Prevalence of Fabry Disease in a Cohort of 508 Unrelated Patients With Hypertrophic Cardiomyopathy Lorenzo Monserrat,
Multiple sclerosis – late onset. Authors: Vitalie Vacaras Vitalie Vacaras Damian Popescu Damian Popescu Radu Antonescu Radu Antonescu Anca Simu Anca Simu.
PRADER WILLI Syndrome.
Clinical characterization of six patients with 15q13. 2-q13
Characterization of VHL promoter variants in patients suspected of Von Hippel Lindau Saleh Albanyan, Rachel Giles, Raymond H Kim, MD/PhD Division of.
Assessing the role of the ALS-associated gene NEK1 in zebrafish motor neuron development Amy Stark.
Monitoring asymptomatic boys
Canavan Disease By Lauren Nieman.
M Waddington Cruz, A Berensztejn, MV Pinto, R Mundayat
Figure Cerebral MRI and molecular and enzymatic analysis
NeuroVia, NV1205 Clinical Trials
Genetics of Pulmonary Diseases
Early Onset of Severe Familial Amyotrophic Lateral Sclerosis with a SOD-1 Mutation: Potential Impact of CNTF as a Candidate Modifier Gene  Ralf Giess,
Figure 2 Characteristic MRI features of adult leukodystrophies
LHON/LHON plus Andrea Gropman, M.D., FAAP, FACMG, FANA
Presentation transcript:

ADDISON IN X-LINK ADRENOLEUKODYSTROPHY (X- ALD): Phenotype and genotype of 12 cases Nguyen Ngoc Khanh 1, Vu Chi Dung 1 , Shimozawa N 2. , Bui Phuong Thao 1, Can Thi Bich Ngoc 1 , Nguyen Thi Hoan 1 , Nguyen Phu Dat 1, Le Thi Kim Ngoc 1 1 Vietnam National Hospital of Pediatrics, Hanoi, Vietnam 2 Division of Genomics Research Life Science Research Center, Department of Pediatrics, Gifu University School of Medicine, Gifu, Japan

BACKGROUND X-linked adrenoleukodystrophy (X-ALD): peroxisomal disorder affecting adrenal cortex & central nervous system. Rare disease: in males (USA): 1/21,000 Symptoms: often in males –Addison: hyperpigmentation, anxious. –Progressive neurologic deficit: cognitive deficit, visual deficit, hearing deficit, motor dysfunction… –May be in females: often over 30 years old with increased deep tendon reflexes and distal sensory changes in lower extremities…

BACKGROUND Variant phenotypes: 4 types: Cerebral inflammatory ALD, Adrenomyeloneuropathy: AMN, Addison – only, Asymtomatic. Broad phenotype: from childhood cerebral form characterized by rapid progression to a vegetative state or death within 1–2 years (31–35%), to slowly progressive adrenomyeloneuropathy (AMN) in adults (40–46%)

Moser HW et al. (2007) X-linked adrenoleukodystrophy Nat Clin Pract Neurol 3: 140–151 doi: /ncpneuro0421 X-linked adrenoleukodystrophy phenotypes in males THẢO LUẬN

Moser HW et al. (2007) X-linked adrenoleukodystrophy Nat Clin Pract Neurol 3: 140–151 doi: /ncpneuro0421

BACKGROUND The gene that is defective in X-ALD was mapped to Xq28 in 1981 & was isolated & cloned in This gene is now referred to as ABCD1. It is composed of 10 exons, it codes for a messenger RNA of 4.3 kb, & a protein of 745 amino acids that is now referred to as adrenoleukodystrophy protein (ALDP).

BACKGROUND Definitive Diagnosis: –Plasma VLCFA profiles. –Mutations analysis of ABCD1 gene

AIMS To describe clinical, laboratory & cerebral MRI characteristics of Vietnamese patients with X- ALD To identify mutations of ABCD1 in these cases

PATIENTS & METHODS 12 cases from 10 unrelated families Case series study Clinical & imagine at NHP, Hanoi, Vietmam Extraction of DNA from peripheral blood leukocyte using standard procedures VLCFA profile & mutation analysis of ABCD1 at Gifu University, Japan

RESULTS PHENOTYPE (1): onset – diagnosis: 0.25 – 11 yrs PatientFamily history Age of onset of addison (yrs) Age of onset of neurologic symptoms (yrs) Age of diagnosis (yrs) Time onset to diagnosis (yrs) 1+5(-) until (sibling of pt 1) (-) until * *-(+) age NA No

RESULTS PHENOTYPE (2): onset – diagnosis: 0.25 – 11 yrs PatientFamily history Age of onset of addison (yrs) Age of onset of neurologic symptoms (yrs) Age of diagnosis (yrs) Time onset to diagnosis (yrs) 7-1.7(-) tới 4.3 tuổi , brother of ,56,30, ,65, ,39,60,3

RESULTS Neurologic symptoms Neurologic symptomsN Cognitive deficit (poor learning, neglect) 9/9 Attention deficit9/9 Behaves deficit7/9 Visual dysfunction6/9 Hearing dysfunction6/9 Speech difficulty6/9 Motor dysfunction6/9

RESULTS Adrenal function & Brain MRI PatientCortisol at 8 AM ( nmol/l) ACTH (7.2 – 63.3 pg/ml) Brain MRI Normal at 11 yrs 27952Marked loss of posterior white matter Normal at 4.7 yrs 4*121134Reduced density in white part in occipital areas 5* Marked loss of posterior white matter

RESULTS Adrenal function & Brain MRI (2) PatientCortisol at 8 AM ( nmol/l) ACTH (7.2 – 63.3 pg/ml) Brain MRI 6NA bilateral white matter lesions (Loes 14) 723NANormal at 4.3 yrs White matter lesion (Loes 4) 9NA

RESULTS Adrenal function & Brain MRI (3) BNCortisol 8 AM ( nmol/l) ACTH (7.2 – 63.3 pg/ml) MRI Sọ não Cerebral atrophy, billateral white matter lesion in thalamus, corpus callosum, cerabellum (Loes: 16) ,89 Bilateral white matter lesion in periventricular, thalamus, corpus callosum. (Loes: 12) 1241,1172 Bilateral white matter lesion in periventricular, thalamus, corpus callosum. (Loes: 10)

RESULTS VLCFA Profile (1) PatientC24:0/C22:0 (1.05 ±0.16) C25:0/C22:0 (0.024 ±0.006) C26:0/C22:0 (0.012 ±0.005) (sib of pt 1) *NA 5*

RESULTS VLCFA Profile (2) PatientC24:0/C22:0 (1.05 ±0.16) C25:0/C22:0 (0.024 ±0.006) C26:0/C22:0 (0.012 ±0.005) NA 11NA 12NA

RESULTS Genotype Patientc.DNAMutant protein 1c.1628C>Tp.Pro543Leu 2 (sib of pt 1) c.1628C>Tp.Pro543Leu 3c.1553G>Ap.Arg518Gln 4*c.1202G>Tp.Arg401Trp 5*c.1208T>Ap.Met403Lys *Novel mutation

RESULTS Genotype (2) Patientc.DNAMutant protein 6*6* deletion included between IVS1+505 and IVS2+1501, containing whole exon 2 (4243bp), plus insertion of 79bp from BAP31 and 8bp from unknown origin 7*7* IVS bp del 8c.1552 C>Tp.Arg518Trp 9 (sibling of pt 8) c.1552 C>Tp.Arg518Trp 9 different mutations including 4 *novel

RESULTS Genotype (3) Patientc.DNAMutant protein 10c.46-53del insG 11c.854G>Cp.R285P 12NA 9 different mutations including 4 *novel

CONCLUSION Onset – diagnosis: 0.25 – 11 yrs Addison in 9/12 cases; progressive neurologic dysfunction in 9/12 cases 6 cases: Addison + progressive neurologic dysfunction 3 cases: progressive neurologic dysfunction 3 cases: Addison Cognitive deficit, attention deficit were 1 st neurologic symptoms (9/9). Behave deficit, visual dysfunction, hearing dysfunction, motor dysfunction, speech difficulty were later.  Easy to misdiagnosis

CONCLUSION Low plasma cortisol & high ACTH levels in 7/7 Brain MRI: abnormal in 8/8 cases with neurologic symptoms. 7/8 had Loes score >10, only 1 case 8 had Loes 4.  Brain MRI: important to decide HSCT  Definitive diagnosis: Increasing of plasma VLCFA in 8/8 Nine different mutations of ABCD1 including 4 novel ones Same family & same genotype but without neurologic symptoms in older boy (pt 1)

T.D.H (Pt1) 11.5 years old T.Q.N (Pt2) 9 years old Pt 1 DOB: 1/1/2000 Hyperpigmentation No neurologic symptoms p.543Pro>Leu Pt 2 DOB: 22/4/2002 Hyperpigmentation Neurologic symptoms p.543Pro>Leu

T.D.H (Pt1) 11.0 years old T.Q.N (Pt2) 9 years old ABCD1 ex6 c.1628C>T (p.543Pro>Leu)

H.D.M.T (Pt 3)4.7 years old; ABCD1 ex6 c.1553G>A p.518Arg>Gln

N.C.H Novel mutation c.1202G>T (p.Arg401Trp) Healthy Carrier p.Arg401Trp Died at 7 years of age Died at 12 years of age I II III IV Pt 4. Pedigree of N.C.H

N.C.H (pt 4)

Pt 6. Nguyen Van Q Extent of deletion included between IVS1+505 and IVS2+1501, containing whole the exon 2 (4243bp), plus insertion of 79bp from BAP31 and 8bp from unknown origin 9.75 yrs. From 9.5 yrs of age: pain of legs, weakness, difficulties of pronunciation, poor hearing, poor vision, no hyperpigmentation.

Trương Xuan H 11 yrs c.1552 C>T (p.Arg518Trp) p.Arg518Trp Pt 8

Trương Xuan H 11 yrs VLCFA Profile Pt : ALD control; 3860: Pt 8; 3861: Pt 9; 3769 normal control

Thank you very much!